New funds will be used to expand world’s largest human genomic data portal

Cambridge, 4 April 2017Repositive, the company that created the world’s largest portal for accessing human genomic research data, has closed a Series A funding round of £2.5m.

 The investors include lead investor, Ananda Social Venture Fund, Force Over Mass Capital and sees Amadeus Capital Partners and Jonathan Milner increase their investments, having previously participated in seed funding Repositive. This brings the total funds raised to date in Repositive to £3.3m.  

Fiona Nielsen, CEO of Repositive, said: “This investment will allow Repositive to expand its commercial offering through the development of premium features for our fast growing community of platform users worldwide. Alongside this, we will invest further in expanding the range of data sources on our platform and developing further commercial products and services for the genomics R&D industry. I am delighted to welcome Ananda as lead investor and to see the continued support of Amadeus Capital Partners and Jonathan Milner.” 

Lennart Hergel, Investment Director for Ananda Social Venture Fund commented: “Repositive is unique in identifying, providing access and democratising genomic data without ethical compromise. We believe that this will reduce time and cost for diagnostics and drug development, therefore enabling better and affordable access to new and personalized therapies for patients. We have confidence that the energetic and capable Repositive team will drive this impact and create a very successful company on a commercial level.” 

Jonathan Milner added: “Repositive have made great progress in building their platform and the community it supports. With plans to commercialise the platform this year, Repositive are in a strong position to become a commercial and scientific global success.” 

Pierre Socha, Principal, Amadeus Capital Partners, said: “Since the initial seed funding round, the Repositive team has made excellent progress in developing its platform. With a growing user base, including many of the world’s largest pharma companies, and a series of global partnerships, Repositive is strongly positioned for future growth.” 

Since its launch in September 2016, the community-driven Repositive platform has grown to over one million data sets and the company has expanded their global user base across pharma, biotech and academia. Alongside this, the company has secured a number of significant partnerships with leading genetic research and pharma companies in oncology, through the Repositive PDX Consortium.

For further information, please contact:
Tony Stephenson
Exitus Communications
Tel: +44 (0)7899 796655

About Repositive: 
Repositive are experts in the provision of efficient access to genomic data. Through their platform, researchers and scientists are able to quickly and easily access data from a range of global sources, and securely make their data accessible to both internal and external collaborators. The Repositive platform enables researchers to interact with the research community to identify more relevant data, and benefit from the community feedback and data annotations. From their headquarters in Cambridge, the Repositive team of experts in genomics, data access policies and effective metadata management, also offer a range of services to corporate customers including large-scale enterprise solutions.

About Amadeus Capital Partners:
Amadeus Capital Partners is a global technology investor. Since 1997, the firm has backed more than 120 companies and raised over $1bn for investment. 

With vast experience and a great network, Amadeus Capital’s team of investors and entrepreneurs share a passion for the transformative power of technology. We invest in consumer services, financial technology, artificial intelligence, cyber security, medical technology, digital health and digital media.

Early stage investments we’ve made include genomic research data collaboration platform Repositive, massively parallel simulation platform, Graphcore, innovators in intelligent microprocessors, and speech recognition company VocalIQ.

To learn more visit or follow us at @AmadeusCapital.

About Ananda: 
Ananda Ventures (Social Venture Fund I and II) manages €30m and is the first social impact investor with a pan European focus. Social Venture Fund invests in outstanding social enterprises, which provide innovative solutions for urgent social challenges. The Social Venture Funds’ active portfolios include “Auticon”, a company providing IT consulting delivered by Asperger autists, “VerbaVoice”, a mobile transcription solution for hearing impaired People, Third Space Learning, providing Math tutoring to disadvantaged.